1. A resin composition containing a graft copolymer obtained by reacting
1 to 99 parts by weight of (a) an amino group-containing hydrogenated block copolymer obtained through hydrogenation of an amino group-containing block copolymer with
99 to 1 part by weight of (b) a functional group-containing polyphenylene ether having any one functional group selected from the group consisting of a carboxyl group, an acid anhydride group and an epoxy group andor (c) a functional group-containing polyolefin having any one functional group selected from a group consisting of a carboxyl group, an acid anhydride group and an epoxy group,
wherein the amino group-containing block copolymer is obtained by reacting a living terminal lithium ion group of a vinyl aromatic compound-conjugated diene compound block copolymer chain, which is formed using an organic lithium compound as a polymerization initiator in a hydrocarbon solvent with a cyclic compound represented by the following formula (1) or (2),
wherein R1 and R2 are independently of each other an alkyl or alkoxy group having 1 to 4 carbon atoms, Y is an oxygen atom or a sulfur atom, and n is an integer of 2 to 4,
wherein R3 is an alkyl, cycloalkyl or alkoxy group having 1 to 6 carbon atoms, Z is an oxygen atom or a sulfur atom, and m is an integer of 3 or 4, provided that one or more hydrogen atoms in the polymethylene chain may be substituted with an alkyl group having 1 to 6 carbon atoms.
2. A resin composition comprising
1 to 99 parts by weight of a resin composition containing a graft copolymer obtained by reacting
1 to 99 parts by weight of (a) an amino group-containing hydrogenated block copolymer obtained through hydrogenation of an amino group-containing block copolymer with
99 to 1 part by weight of (b) a functional group-containing polyphenylene ether having any one functional group selected from the group consisting of a carboxyl group, an acid anhydride group and an epoxy group andor (c) a functional group-containing polyolefin having any one functional group selected from a group consisting of a carboxyl group, an acid anhydride group and an epoxy group,
wherein the amino group-containing block copolymer is obtained by reacting a living terminal lithium ion group of a vinyl aromatic compound-conjugated diene compound block copolymer chain, which is formed using an organic lithium compound as a polymerization initiator in a hydrocarbon solvent with a cyclic compound represented by the following formula (1) or (2),
wherein R1 and R2 are independently of each other an alkyl or alkoxy group having 1 to 4 carbon atoms, Y is an oxygen atom or a sulfur atom, and n is an integer of 2 to 4,
wherein R3 is an alkyl, cycloalkyl or alkoxy group having 1 to 6 carbon atoms, Z is an oxygen atom or a sulfur atom, and m is an integer of 3 or 4, provided that one or more hydrogen atoms in the polymethylene chain may be substituted with an alkyl group having 1 to 6 carbon atoms, and
99 to 1 part by weight of (d) a thermoplastic resin excepting the above-defined components (a) to (c).
3. A resin composition comprising a resin composition comprising
1 to 99 parts by weight of a resin composition containing a graft copolymer obtained by reacting
1 to 99 parts by weight of (a) an amino group-containing hydrogenated block copolymer obtained through hydrogenation of an amino group-containing block copolymer with
99 to 1 part by weight of (b) a functional group-containing polyphenylene ether having any one functional group selected from the group consisting of a carboxyl group, an acid anhydride group and an epoxy group andor (c) a functional group-containing polyolefin having any one functional group selected from a group consisting of a carboxyl group, an acid anhydride group and an epoxy group,
wherein the amino group-containing block copolymer is obtained by reacting a living terminal lithium ion group of a vinyl aromatic compound-conjugated diene compound block copolymer chain, which is formed using an organic lithium compound as a polymerization initiator in a hydrocarbon solvent with a cyclic compound represented by the following formula (1) or (2),
wherein R1 and R2 are independently of each other an alkyl or alkoxy group having 1 to 4 carbon atoms, Y is an oxygen atom or a sulfur atom, and n is an integer of 2 to 4,
wherein R3 is an alkyl, cycloalkyl or alkoxy group having 1 to 6 carbon atoms, Z is an oxygen atom or a sulfur atom, and m is an integer of 3 or 4, provided that one or more hydrogen atoms in the polymethylene chain may be substituted with an alkyl group having 1 to 6 carbon atoms, and
99 to 1 part by weight of (d) a thermoplastic resin excepting the above-defined components (a) to (c), and
(e) an inorganic filler in an amount of from 1 to 250 parts by weight based on 100 parts by weight of the above-defined resin composition.
4. The resin composition according to any one of claims 1 to 3, wherein a vinyl aromatic compound content in a vinyl aromatic compound-conjugated diene compound block copolymer, which is a precursor of the amino group-containing hydrogenated block copolymer as the component (a), is from 1 to 95% by weight.
5. The resin composition according to any one of claims 1 to 3, wherein the sum of a 1,2-vinyl bond content and a 3,4-vinyl bond content showing a bonding state of the conjugated diene compound in a vinyl aromatic compound-conjugated diene compound block copolymer, which is a precursor of the amino group-containing hydrogenated block copolymer as the component (a), is from 2 to 85% by weight.
6. The resin composition according to any one of claims 1 to 3, wherein the amino group-containing hydrogenated block copolymer as the component (a) is the one obtained by diminishing an olefinically unsaturated bond originated from the conjugated diene compound present in the precursor amino group-containing block copolymer chain to the extent of not more than 90%.
7. The resin composition according to any one of claims 1 to 3, wherein a number average molecular weight of an unmodified polyphenylene ether, which is a precursor of the functional group-containing polyphenylene ether as the component (b) is not less than 1,000 calibrated with polystyrene standard according to GPC.
8. The resin composition according to any one of claims 1 to 3, wherein the functional group-containing polyphenylene ether as the component (b) is an acid anhydride group-containing polyphenylene ether obtained by adding 0.05 to 30 parts by weight of maleic anhydride to 100 parts by weight of the precursor polyphenylene ether.
9. The resin composition according to any one of claims 1 to 3, wherein a polyolefin, which is a precursor of the functional group-containing polyolefin as the component (c) before the addition of functionality, is a polyolefin selected from the group consisting of isotactic polypropylene, poly(4-methyl-1-pentene), polybutene-1, high density polyethylene, ultra high molecular weight high density polyethylene, low density polyethylene, linear low density polyethylene, ultra low density polyethylene having density of lower than 0.90 and a copolymer of ethylene and propylene or other \u03b1-olefins, which is substantially freed from a carboxyl group, an acid anhydride group, an epoxy group and other functional groups originated from a copolymerization monomer.
10. The resin composition according to any one of claims 1 to 3, wherein the functional group-containing polyolefin as the component (c) is an acid anhydride group-containing polyolefin obtained by adding 0.05 to 30 parts by weight of maleic anhydride to 100 parts by weight of the precursor polyolefin.
11. The resin composition according to claim 2 or 3, wherein the thermoplastic resin as the component (d) is at least one member selected from the group consisting of polyolefins, styrenic resins, polyamides, polyesters, polyphenylene ethers, polyphenylene sulfides and liquid crystal polyesters.
12. The resin composition according to claim 11, wherein the polyolefin as the component (d) is at least one polyolefin selected from the group consisting of isotactic polypropylene, poly(4-methyl-1-pentene), polybutene-1, high density polyethylene, ultra high molecular weight high density polyethylene, low density polyethylene, linear low density polyethylene, ultra low density polyethylene having density of lower than 0.90 and a copolymer of ethylene and propylene or other \u03b1-olefins, which is substantially freed from a carboxyl group, an acid anhydride group, an epoxy group and other functional groups originated from a copolymerization monomer.
13. The resin composition according to claim 11, wherein the styrenic resin as the component (d) is at least one member selected from the group consisting of atactic polystyrene, and syndiotactic polystyrene.
14. The resin composition according to claim 11, wherein the polyamide as the component (d) is at least one member selected from the group consisting of polyamide 6, polyamide 6, 6, polyamide 4, 6, polyamide 11, polyamide 12, polyamide 6, 10, polyamide 6, 12, polyamide 66, 6, polyamide 66, 12, polyamide MXD (m-xylylenediamine)6, polyamide 6, T, polyamide 6, I, polyamide 66, T, polyamide 66, I, polyamide 6, 66, T, polyamide 6, 66, I, polyamide 66, T6, I, polyamide 6,66, T6, I, polyamide 6126, T, polyamide 6, 6126, T, polyamide 6126, I, polyamide 6, 6126, I, poly(p-phenyleneterephthalamide), poly(p-benzamide), poly(4,4\u2032-benzanilideterephthalamide), poly(p-phenylene-4,4\u2032-biphenylenedicarboxyamide), poly(p-phenylene-2,6-naphthalenedicarboxyamide), poly(2-chloro-p-phenyleneterephthalamide) and p-phenylenediamine2,6-dichloro-p-phenylenediamineterephthalic dichloride copolymer.
15. The resin composition according to claim 11, wherein the polyester as the component (d) is at least one member selected from the group consisting of polyethylene terephthalate, polytrimethylene terephthalate and polybutylene terephtalate.
16. The resin composition according to claim 2 or 3, wherein the thermoplastic resin as the component (d) is at least two members selected from the group consisting of polyphenylene sulfides, polyethylene terephthalates, polytrimethylene terephthalates, polybutylene terephthalates, polyphenylene ethers, polycarbonates, ethylene-glycidyl methacrylate copolymers, styrene-glycidyl methacrylate copolymers and styrene2-isopropenyl-2-oxazoline copolymers.
17. The resin composition according to claim 3, wherein the inorganic filler as the component (e) is at least one member selected from the group consisting of an inorganic salt, glass fiber, glass flake, glass beads, carbon fiber, whisker, mica, talc, carbon black, titanium oxide, calcium carbonate, potassium titanate,
wallastonite, a heat conductive substance such as graphite, aluminum nitride, boron nitride, alumina, beryllium oxide, silicon dioxide, magnesium oxide, aluminum nitrate or barium sulfate, electrically conductive metal fiber, electrically conductive metal flake, electrical conductivity-carrying carbon black or electrical conductivity-carrying carbon fiber.
18. A process for producing the resin composition according to any of claim 2 or 3, comprising heat-melt-kneading the component (a) and the component (b) andor the component (c) with use of a heat melt kneading machine set at a temperature of not lower than 150\xb0 C.
19. The resin composition according to any one of claims 1 to 3,
wherein the functional group-containing polyphenylene ether as the component (b) is obtained by adding a functional group-containing compound selected from the group consisting of a carboxyl group containing compound, an acid anhydride-containing compound and an epoxy group-containing compound to a precursor polyphenylene ether,
wherein the functional group-containing polyolefin as the component (c) is obtained by adding a functional group-containing compound selected from the group consisting of a carboxyl group containing unsaturated compound, an acid anhydride-containing unsaturated compound and an epoxy group-containing unsaturated compound to a precursor polyolefin.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating breast cancer comprising
experimentally obtaining a dataset associated with a sample derived from a patient diagnosed with cancer, wherein the dataset comprises:
expression data for at least one marker selected from the group consisting of FLJ10517, HCAP-G, CDKN3, STK6, FOXM1, FLJ10540, TNFRSF6B, HBP17, C1QDC1, TUBG1, FLJ10036, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, and ODC1 andoptionally at least one clinical factor;
determining a predictive score from the dataset using an interpretation function, wherein
the predictive score is predictive of the response to the cancer treatment; and
administering a therapeutically effective amount of the cancer treatment to the patient who is predicted to respond to the cancer treatment.
2-7. (canceled)
8. The method of claim 1, wherein the determining is determined by a computer processor.
9. The method of claim 1, wherein the dataset further comprises the expression data and the at least one clinical factor.
10. The method of claim 9, wherein the at least one clinical factor term is selected from the group consisting of age, gender, neutrophil count, ethnicity, race, disease duration, diastolic blood pressure, systolic blood pressure, a family history parameter, a medical history parameter, a medical symptom parameter, height, weight, a body-mass index, smokernon-smoker status, ER status, HER2 status, tumor size, tumor grade, luminal A characterization, luminal B characterization, basal-like, and normal-like.
11. The method of claim 1, wherein the predictive score is compared to a score derived from a sample from a patient with cancer that was known to have responded or not responded to chemotherapy,
wherein a sample whose score matches the predetermined predictive of sample derived from a patient that responded to treatment the patient diagnosed with cancer is predicted to respond to the cancer treatment, or
wherein a sample whose score matches the predetermined predictive of sample derived from a patient that did not respond to treatment the patient diagnosed with cancer is predicted to not to respond to the cancer treatment.
12. (canceled)
13. The method of claim 1, wherein said response is a complete response, partial response no response, a pathological complete response, at least 5 year survival, or a relapse-free survival.
14-16. (canceled)
17. The method of claim 1, wherein the interpretation function is based upon a predictive model.
18. The method of claim 17, wherein the predictive model is a logistical regression model, wherein the logistic regression model is applied to the dataset to interpret the dataset to produce the predictive score, wherein a predictive score above a specified cut-off value predicts responsiveness and a predictive score below a specified cut-off predicts non-responsiveness.
19. (canceled)
20. The method of claim 19, wherein the specified cut-off is selected from the group consisting of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9.
21.-23. (canceled)
24. The method of claim 1, wherein the patient diagnosed with breast cancer has an ER-positive breast cancer, ER-negative breast cancer, a breast cancer characterized as Luminal B, a breast cancer characterized as basal-like, or a triple-negative breast cancer.
25-28. (canceled)
29. The method of claim 1, wherein the cancer treatment is adjuvant chemotherapy andor neoadjuvant chemotherapy.
30. The method of claim 1, wherein the cancer treatment is a treatment selected from the group consisting of: TFAC (combination of taxolfluorouracilanthracyclinecyclophosphamide) TAC (taxolanthracyclinecyclophosphamide with or without filgrastim support), ACMF (doxorubicin followed by cyclophosphamide, methotrexate, fluorouracil), ACT (doxorubicin, cyclophosphamide followed by taxol or docetaxel), A-T-C (doxorubicin followed by paclitaxel followed by cyclophosphamide), CAFFAC (fluorouracildoxorubicincyclophosphamide), CEF (cyclophosphamideepirubicinfluorouracil), AC (doxorubicincyclophosphamide), EC (epirubicincyclophosphamide), AT (doxorubicindocetaxel or doxorubicintaxol), CMF (cyclophosphamidemethotrexatefluorouracil), cyclophosphamide (Cytoxan or Neosar), methotrexate, fluorouracil (5-FU), doxorubicin (Adriamycin), epirubicin (Ellence), gemcitabine, taxol (Paclitaxel), GT (gemcitabinetaxol), taxotere (Docetaxel), vinorelbine (Navelbine), capecitabine (Xeloda), platinum drugs (Cisplatin, Carboplatin), etoposide, and vinblastine.
31-36. (canceled)
37. The method of claim 1, the method further comprising extracting RNA from breast epithelial cells.
38. The method of claim 1, the method further comprising hybridizing the sample with one or more probes to produce the expression data.
39. The method of claim 1, the method further comprising performing polymerase chain reaction to produce the expression.
40. (canceled)
41. A system for predicting a response to a cancer treatment comprising a storage memory for storing a dataset associated with a sample obtained from the subject, wherein the dataset comprises expression data for at least one marker selected from the group consisting of FLJ10517, HCAP-G, CDKN3, STK6, FOXM1, FLJ10540, TNFRSF6B, HBP17, C1QDC1, TUBG1, FLJ10036, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, and ODC1; and a processor communicatively coupled to the storage memory for determining a score with an interpretation function wherein the score is predictive of response to a cancer treatment in a subject diagnosed with cancer.
42. (canceled)
43. The system of claim 41, wherein the cancer is breast cancer.
44. A kit for predicting response to a cancer treatment in a subject comprising one or more reagents for determining from a sample obtained from a subject expression data for at least one marker selected from the group consisting of FLJ10517, HCAP-G, CDKN3, STK6, FOXM1, FLJ10540, TNFRSF6B, HBP17, C1QDC1, TUBG1, FLJ10036, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, and ODC1; and instructions for using the one or more reagents to determine expression data from the sample, wherein the instructions include instructions for determining a score from the dataset wherein the score is predictive of response to the cancer treatment.
45-46. (canceled)
47. The kit of claim 44, wherein the cancer treatment is a breast cancer treatment.
48. The kit of claim 44, wherein the cancer treatment comprises a nitrogen mustard, a vinca alkaloid, an epothilones, a taxane, a mitotic inhibitor, a corticosteroid, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an anti-tumor antibiotics, an anthracycline, an antimetabolite, an ethylenimine, an alkyl sulfonate, a nitrosourea, or any combination thereof.
49-50. (canceled)
51. A method for predicting a response to a cancer treatment in a patient diagnosed with cancer comprising:
isolating a sample of the cancer from the patient diagnosed with cancer;
obtaining a dataset associated with a sample derived from a patient diagnosed with cancer, wherein the dataset comprises expression data for at least one marker selected from the group consisting of FLJ10517, HCAP-G, CDKN3, STK6, FOXM1, FLJ10540, TNFRSF6B, HBP17, C1QDC1, TUBG1, FLJ10036, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, and ODC1 and at least one clinical factor; and
determining a predictive score from the dataset using an interpretation function,
wherein the interpretation function comprises is based upon a predictive model,
wherein the predictive model is a logistical regression model,
wherein the logistical regression model is applied to the dataset to interpret the dataset to produce the predictive score, and
wherein a predictive score above a specified cut-off value predicts responsiveness and a predictive score below a specified cut-off predicts non-responsiveness.